Tendersinfo Gulf

Filter Search

Healthcare and Medical

Location Summary Deadline
Germany Conclusion Of Non-exclusive Discount Agreements According To § 130a Para. 8 Sgb V For The Mentioned Active Ingredients With The Possibility Of Conclusion Within The Framework Of The So-called Open House Procedure. 2026-06-03
Germany Conclusion Of Non-exclusive Discount Agreements According To § 130a Para. 8 Sgb V For The Mentioned Active Ingredients With The Possibility Of Conclusion Within The Framework Of The So-called Open House Procedure. 2026-06-03
Germany Conclusion Of Non-exclusive Discount Agreements According To § 130a Para. 8 Sgb V For The Mentioned Active Ingredients With The Possibility Of Conclusion Within The Framework Of The So-called Open House Procedure. 2026-06-03
Germany Medicines With The Designation Botox (r) (atccode 2026-06-03
United States Chemicals 2026-06-03
Germany Medicines With The Active Ingredient Raltegravir (atc 2026-06-03
Germany The Subject Of This Publication Is The Conclusion Of Non-exclusive Discount Agreements According To § 130a Abs. 8 Sgb V For Medicines Containing The Active Ingredient Latanoprost/timolol (atc-code: S01ed61), Excluding Medicines With Package Size Labels (n 2026-06-03
Germany Conclusion Not Excluding Drug Discount Agreement. In Accordance With Section 130a Paragraph 8 Sgb V Through An Open House Model For The Active Ingredient Lisdexamfetamine, Exclusive Hard Capsules/capsules In A Pack Size Of 30 2026-06-03
United States Notice- Osp Seeking Locum Tenens Forensic Pathologists 2026-06-03
Germany Conclusion Not Excluding Drug Discount Agreement. In Accordance With Section 130a Paragraph 8 Sgb V By Means Of An Open House Model For The Active Ingredient Latanoprost/timolol (official Atc Code: S01ed61), Excluding N1, N2 And N3 2026-06-03
Whats app